Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 4Breast 4Gastrointestinal 3Tumor-Agnostic 2Other solid neoplasm 2Plasma cell 1NET 1Endocrine 1

Conditions

Solid Tumors 1Advanced Solid Tumors 1

Interventions

Cisplatin 81Gemcitabine 58Carboplatin 57Irinotecan 56Paclitaxel 53Pemetrexed 47Docetaxel 39Nivolumab 33Fluorouracil 30Bevacizumab 27pembrolizumab 25Cyclophosphamide 24Capecitabine 24Oxaliplatin 22Leucovorin 21Topotecan 19durvalumab 17Erlotinib Hydrochloride 17Sorafenib 16Everolimus 16Etoposide 16Bortezomib 16Ipilimumab 15Injections 15Sunitinib 14Filgrastim 14Early Intervention, Educational 14atezolizumab 13alvocidib 13Sirolimus 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × dalotuzumab × Other solid neoplasm × Clear all
NCT00635778 2018-10-09

MK-0646-002

Merck Sharp & Dohme LLC

Phase 1 Completed
50 enrolled 32 charts
Other solid neoplasm

Advanced Solid Tumors

NCT01431547 2016-06-17

Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)

Merck Sharp & Dohme LLC

Phase 1 Completed
21 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡